Most of the companies listed here are probably familiar to everyone in one way or another. It's not just stock market players who are familiar with BioNTech, AstraZeneca and Moderna, but probably the vast majority of people who were affected by the global coronavirus pandemic between 2020 and 2023. In industry terms, this is a small proportion of the pharmaceutical companies colloquially referred to as biotech stocks. However, the binding criterion for a Themefolio here is not sector affiliation, but that the players have collectively left their fingerprint on the pandemic. The price movements of the past are visual witnesses. The gold-rush mood was then followed by great lethargy. The future will show which of the NewComers will manage to meet the market's expectations.